Compare Applied Materials, Inc. (AMAT) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applied Materials, Inc. vs ClearPoint Neuro Inc — how do they compare? Applied Materials, Inc. trades at $580.95 (market cap $478.36B), while ClearPoint Neuro Inc trades at $16.67 (market cap $524.82M). The key difference: Applied Materials, Inc. is far larger — about 911.5× ClearPoint Neuro Inc's market cap, and Applied Materials, Inc. pays a 0.35% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| AMAT | CLPT | |
|---|---|---|
Market Cap | $478.36B | $524.82M |
Sector | Technology | Health |
52-Week High | $723.00 | $29.60 |
52-Week Low | $156.25 | $8.66 |
Enterprise Value | $477.39B | $552.81M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Materials (AMAT) trades at $602.50, up 2.35% recently, with strong technical support near $573 and resistance at $617. The company demonstrates robust fundamentals, including a 29.31% net income margin and consistent earnings beats, while benefiting from AI-driven semiconductor demand highlighted in recent CEO commentary (CNBC, 2026-05-28).
Outlook remains positive given analyst consensus of $644.33 price target and 76.9% buy ratings, though elevated P/E of 56.68 poses valuation risk. Key opportunities include AI infrastructure growth, while risks involve cyclical semiconductor demand and execution challenges in scaling operations.
ClearPoint Neuro (CLPT) trades at $17.50, down 2.13% on the day, with a bullish technical signal from moving averages despite recent earnings misses. The company reported record Q1 2026 revenue of $41M with 43% growth but continues to post significant net losses, reflected in a negative net income margin of -71.57%. Recent FDA clearance for its Velocity Alpha surgical drill and a new partnership in South Korea highlight ongoing business development efforts.
The investment case hinges on CLPT's positioning in the gene therapy enabling space, with 100% analyst buy ratings supporting long-term growth potential. However, persistent cash burn, regulatory dependencies on partner therapies like AMT-130, and execution risks present substantial challenges. Investors face high volatility given the speculative nature of its growth trajectory against current profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
